Piper Sandler downgraded Sutro Biopharma (STRO) to Neutral from Overweight with a price target of $2, down from $8. The company is deprioritizing development of luvelta in order to focus resources on its early stage antibody-drug conjugates pipeline, the analyst tells investors in a research note. Piper downgraded Sutro after removing luvelta value.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Sutro Biopharma double downgraded at BofA after luvelta deprioritized
- Sutro Biopharma downgraded to Underperform from Buy at BofA
- Cautious Hold Rating on Sutro Biopharma Amid Strategic Shift and Restructuring
- Sutro Biopharma’s Strategic Shift: Hold Rating Amid Reprioritization and Financial Restructuring
- Sutro Biopharma downgraded to Neutral from Outperform at Wedbush